1. Home
  2. SMID vs SPRO Comparison

SMID vs SPRO Comparison

Compare SMID & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$35.11

Market Cap

151.1M

Sector

Industrials

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.55

Market Cap

135.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMID
SPRO
Founded
1960
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.1M
135.5M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
SMID
SPRO
Price
$35.11
$2.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.1K
422.4K
Earning Date
04-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
62.76
111.81
EPS
2.36
0.15
Revenue
$93,446,000.00
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
$14.92
$16.77
Revenue Growth
19.03
39.24
52 Week Low
$25.60
$0.65
52 Week High
$43.62
$3.09

Technical Indicators

Market Signals
Indicator
SMID
SPRO
Relative Strength Index (RSI) 63.36 48.94
Support Level $35.80 $2.15
Resistance Level $36.89 $2.70
Average True Range (ATR) 1.32 0.11
MACD 0.26 -0.03
Stochastic Oscillator 100.00 30.10

Price Performance

Historical Comparison
SMID
SPRO

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: